Consequently, food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.

Beyond weight loss: protecting muscle with GLP-1s. Dr Almandoz shares strategies to preserve muscle, optimize body composition, and enhance health outcomes during GLP-1 therapy.

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...

These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...